

GenBio Sees Early International Partnering Interest Ahead of 2026 Asia Bio Partnering Forum

GenBio has received multiple meeting invitations, including interest from an established South Korean clinical research organization.

ALISO VIEJO, CA, UNITED STATES, August 12, 2026 /EINPresswire.com/ -- GenBio Inc., a U.S.-based biotechnology company advancing novel therapeutic programs derived from its proprietary scientific platform, today announced that it has received inbound interest from an established South Korean clinical research and laboratory organization regarding a prospective meeting with GenBio management.



Since conference networking opened on August 3, GenBio has received multiple invitations to engage with participants across the biotechnology and pharmaceutical ecosystem ahead of the 2026 Asia Bio Partnering Forum.



The most important thing in communication is hearing what isn't said."

Peter Ferdinand Drucker

Among those inquiries, management identified interest from an established South Korean clinical research and laboratory organization as particularly relevant to GenBio's

development strategy. The organization provides laboratory capabilities supporting clinical research and drug development within South Korea's sophisticated life-sciences ecosystem.

GenBio has elected not to identify the organization at this preliminary stage in order to preserve the confidentiality of prospective discussions.

"We have been encouraged by the level of engagement since partnering opened," said Giles Tilley, Chief Executive Officer of GenBio Inc. "What stood out about this particular inquiry was its potential relevance to the development of our therapeutic programs. Our objective in participating in Asia Bio is not simply to generate meetings, but to identify organizations whose capabilities could meaningfully complement the science GenBio is advancing."

The interest follows GenBio's expanding engagement across the Asia-Pacific biotechnology and pharmaceutical community and comes as the Company continues to introduce its scientific platform and therapeutic development programs to potential strategic participants internationally.

"Asia has become an increasingly important part of the global biotechnology and pharmaceutical development landscape," said Todd D. Sonoga, Chief Marketing Officer of GenBio Inc. "We are encouraged when established organizations within that ecosystem take an interest in understanding GenBio's science and development programs. These are precisely the types of conversations we hoped to generate through our increased international engagement."

GenBio's research activities center on the identification, purification and characterization of biologically active components originating from rare natural sources and their potential application to significant therapeutic challenges.

The Company's research and development programs include work addressing antimicrobial resistance, inflammatory pathways and colorectal cancer, supported by international scientific



Peter Ferdinand Drucker was an Austrian-born American management consultant, educator, and author widely regarded as the father of modern management



Accelerating biopharma and medtech advancements through innovation, capital and partnerships.

collaborations and ongoing intellectual-property development.

GenBio is currently expanding discussions with pharmaceutical companies, biotechnology organizations, clinical-development groups and other strategic participants as management evaluates pathways capable of advancing its scientific discoveries toward broader development and commercialization.

About GenBio Inc.

GenBio Inc. is a U.S.-based biotechnology company focused on identifying, refining and developing biologically active compounds derived from rare natural sources. Through international scientific collaborations, GenBio is advancing research programs targeting significant areas of unmet medical need while developing intellectual property around its discoveries and therapeutic applications.

Developed by Nature. Identified, Refined and Formulated by GenBio.

Forward-Looking Statements

This press release may contain forward-looking statements regarding GenBio Inc.'s research programs, prospective discussions, development activities, intellectual property, strategic initiatives and potential future relationships. Such statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results or developments to differ materially. Prospective discussions may not result in any collaboration, agreement, transaction or other commercial relationship. GenBio undertakes no obligation to update forward-looking statements except as required by applicable law.

Media & Corporate Inquiries

GenBio Inc.

www.genbioinc.com

Todd D. Sonoga

GenBio Inc.

+1 949-705-8021

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/933655338>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.